Literature DB >> 15083784

A catalog of dermatology utilities: a measure of the burden of skin diseases.

Suephy C Chen1, Ahmed M Bayoumi, Seaver L Soon, Kent Aftergut, Ponciano Cruz, Shenara A Sexton, Calvin O McCall, Mary K Goldstein.   

Abstract

Utilities are measures of quality of life that reflect the strength of individuals' preferences or values for a particular health outcome. As such, utilities represent a measure of disease burden. The aim of this article is to introduce the concept of utilities to the dermatology community and to present a catalog of dermatology utilities obtained from direct patient interviews. Our data are based on 236 total subjects from Grady Hospital (Atlanta, GA), Stanford Medical Center (Palo Alto, CA), and Parkland Hospital (Dallas, TX). The mean time trade-off utilities ranged from 0.640 for blistering disorders to 1.000 for alopecia, cosmetic, and urticaria. The mean utility across all diagnoses was 0.943. We present utilities for 17 diagnostic categories and discuss the underlying reasons for the significant disease burden that these utilities represent. We also present these dermatology categories relative to noncutaneous diseases to place the cutaneous utilities in perspective and to compare the burden of disease. We have demonstrated that skin diseases have considerable burden of disease and provided a preliminary repository of utility data for future researchers and policy makers.

Entities:  

Mesh:

Year:  2004        PMID: 15083784     DOI: 10.1046/j.1087-0024.2003.09112.x

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  21 in total

1.  Discrepancies between the Dermatology Life Quality Index and utility scores.

Authors:  Fanni Rencz; Petra Baji; László Gulácsi; Sarolta Kárpáti; Márta Péntek; Adrienn Katalin Poór; Valentin Brodszky
Journal:  Qual Life Res       Date:  2015-12-18       Impact factor: 4.147

2.  A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.

Authors:  Keith Tolley; Danny Kemmett; Signe Thybo; Ruth Nasr; Helen Smethurst
Journal:  Eur J Health Econ       Date:  2015-03-21

3.  Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.

Authors:  Spencer M Vale; Dane Hill; Steven R Feldman
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

Review 5.  Psoriasis: epidemiology, clinical features, and quality of life.

Authors:  R G B Langley; G G Krueger; C E M Griffiths
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

6.  Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial.

Authors:  Martin A Weinstock; Kachiu C Lee; Mary-Margaret Chren; Kimberly Marcolivio
Journal:  J Am Acad Dermatol       Date:  2009-04-26       Impact factor: 11.527

Review 7.  A review of health utilities across conditions common in paediatric and adult populations.

Authors:  Jean-Eric Tarride; Natasha Burke; Matthias Bischof; Robert B Hopkins; Linda Goeree; Kaitryn Campbell; Feng Xie; Daria O'Reilly; Ron Goeree
Journal:  Health Qual Life Outcomes       Date:  2010-01-27       Impact factor: 3.186

8.  Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.

Authors:  Anna Oh; Dang M Tran; Leann C McDowell; Dor Keyvani; Jay Andrew Barcelon; Oscar Merino; Leslie Wilson
Journal:  J Manag Care Spec Pharm       Date:  2017-06

Review 9.  The contribution of health services research to improved dermatologic care.

Authors:  Mary-Margaret Chren
Journal:  J Invest Dermatol       Date:  2011-11-10       Impact factor: 8.551

10.  Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.

Authors:  Georgia Avgerinou; Ioannis Bassukas; Georgios Chaidemenos; Andreas Katsampas; Marita Kosmadaki; Hara Kousoulakou; Athanasios Petridis; Brad Schenkel; Dimitrios Sotiriadis; Theofanis Spiliopoulos; Panagiotis Stavropoulos; Evgenia Toumpi; Loukas Xaplanteris
Journal:  BMC Dermatol       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.